Subject: Trending Gem - Ticker BSGM Date: Tue, 25 Nov 2014 18:52:44 -0700 X-LibVersion: 3.3.2_4 MIME-Version: 1.0 Content-Type: text/html; charset=iso-8859-1; format=flowed Content-Transfer-Encoding: 8bit X-Priority: 3 X-MSMail-Priority: Normal X-MimeOLE: Produced by SwiftMailer 3.3.2_4 X-Mailer: Administration X-Mailer-MsgId: bG9qYmFuQGxvamJhbi5vcmc= X-Mailer-CSID: MjBfNDA= Message-ID: <20141126015244.5584.1976528637.swift@www.frontpagestocksnewsletter.com> X-Spam-Score: 4.6 (++++) X-Spam_score: 4.6 X-Spam_score_int: 46 X-Spam_bar: ++++ X-Spam-Report: Spam detection software, running on the system "stodi.digitalkingdom.org", has NOT identified this incoming email as spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see @@CONTACT_ADDRESS@@ for details. Content preview: Email Newsletter of this month. Trouble view the email? Click here to see the online version Improving the Quality of Cardiac EP Recordings BioSig Technologies, Inc. (BSGM) is a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP System. [...] Content analysis details: (4.6 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked. See http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block for more information. [URIs: postimg.org] 1.3 RCVD_IN_RP_RNBL RBL: Relay in RNBL, https://senderscore.org/blacklistlookup/ [75.226.28.229 listed in bl.score.senderscore.com] 1.6 URIBL_WS_SURBL Contains an URL listed in the WS SURBL blocklist [URIs: frontpagestocksnewsletter.com] 0.0 HTML_MESSAGE BODY: HTML included in message -0.0 BAYES_40 BODY: Bayes spam probability is 20 to 40% [score: 0.2176] 0.7 MIME_HTML_ONLY BODY: Message only has text/html MIME parts 0.0 LOTS_OF_MONEY Huge... sums of money 1.0 RDNS_DYNAMIC Delivered to internal network by host with dynamic-looking rDNS

Trouble view the email? Click here to see the online version

Improving the Quality of Cardiac EP Recordings

BioSig Technologies, Inc. (BSGM) is a medical device company that has developed a proprietary technology platform designed to greatly improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE EP System.

PURE EP is designed to improve outcomes of EP studies and cardiac catheter ablation, shorten procedure times and reduce recurrence rates. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and provide guidance in identifying ablation targets - areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). BioSig believes this information is not easily obtained, if at all, from any other EP equipment in the market today.

These ablation procedures treat cardiac arrhythmias, which are broadly defined as a set of conditions in which the electrical activity of the heart is irregular, or faster or slower than normal. This type of heart disease afflicts 14.4 million Americans, or one in 18. Two of the most prevalent and deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT).

Abbott Labs purchases similar company:

Topera, Inc. has developed a novel diagnostic catheter and mapping software, or rotor identification system, which help physicians identify and target the specific areas of a person's heart that are perpetuating atrial fibrillation. Under the terms of the acquisition, Abbott will acquire all outstanding equity of Topera for $250 million upfront, plus potential future payments tied to performance milestones.

BioSig Begins Trading with Ticker Symbol BSGM.

According to the American Heart Association, AF increases an individual's risk of stroke (fourth leading cause of death in the US) four to five-fold. AF is the most common arrhythmia with 2.7 million cases in 2010 in the US, forecast to grow to 5.6 million cases by 2050. In the US alone, AF leads to about 600,000 hospitalizations/year with a direct cost of about $6 billion annually and, adding indirect costs, brings the AF total cost to $26 billion.

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate from $2.5 billion in 2012 to $5.5 billion by 2019 making it one of the fastest growing cardiovascular medical technology segments. Just in the US, the number of AF and VT ablations is forecast to grow at 10.5 percent from 2012 to 2017.

BioSig will seek FDA 510 approval for its PURE EP System.

The Company has achieved proof of concept validation through UCLA EP & Animal Labs ongoing from May 2013. BioSig is collaborating with several of the nation's most prestigious cardiac arrhythmia centers to develop, refine and, ultimately, commercialize the PURE EP System, including:

Texas Cardiac Arrhythmia Institute
UCLA Cardiac Arrhythmia Center
U.H. Case Medical Center in Cleveland
William Beaumont Hospital in Michigan
Mount Sinai Medical Center in NY
Mayo Clinic in Minnesota

Brought to you by:

YOUR EMAIL SUBSCRIPTION
Our company reserves the right to contact you via email regarding your account. For details on your information or to cease future offers, please visit our Account Page.

To receive special offer emails from our company or change your email address, manage your email here.

To forward this message to a friend please click on this link.

QUESTIONS OR COMMENTS?
Replies to this email address cannot be answered.

©2014 All other trademarks and service marks are the property of their respective owners.